Li et al. [57] reported that c-FLIPL is transcriptionally regulated by the activator protein-1 (AP-1) family member protein c-Fos, and that MG-132, an inhibitor of the proteasome, sensitizes TRAIL-resistant prostate cancer cells by inducing c-Fos and repressing c-FLIPL. Here, FOS is linked to prostate cancer.